Development of Inno8, an orally administered factor VIIIa-mimetic antibody fragment for treatment of hemophilia A.

Inno8, an orally administered FVIIIa-mimetic antibody fragment, shows 90-fold greater in vitro potency and significant oral bioavailability in preclinical models.

• Why it matters: Oral therapy for hemophilia A remains an unmet need, as current treatments require injections, which can be burdensome and impact patient compliance. Developing an effective oral option could greatly improve quality of life and treatment adherence.
• What they did: Researchers engineered Inno8 from llama and alpaca antibodies, optimizing its structure with machine learning and conjugation techniques, and tested formulations with permeation enhancers in preclinical models, including rats and dogs.
• The result: Inno8 demonstrated enhanced systemic exposure, a long half-life, and promising oral bioavailability, supporting its potential as a potent, long-acting, non-invasive therapy for hemophilia A, now in clinical trials.